摘要
目的:探讨非小细胞肺癌患者血清EGFR基因突变循环DNA检测的临床意义。方法:选取2011年1月-2014年5月于我院接受治疗的124例非小细胞肺癌患者为研究对象,收集血清及组织标本DNA,检测DNA EGFR基因突变情况。结果:124例非小细胞肺癌患者血清EGFR基因检测结果显示:19号外显子突变11例,21号外显子突变8例,血清总检出19例,检出率为15.3%。组织样本中EGFR基因检测结果显示:19号外显子突变27例,21号外显子突变13例,血清总检出40例,检出率为32.3%。在组织样本中,79例男性EGFR基因突变检出14例,比例为17.7%;45例女性EGFR基因突变检出26例,比例为57.8%,相比具有显著性差异(P<0.05)。76例吸烟史患者检出突变16例,比例为21.1%;48例无吸烟史者检出突变24例,比例为50.0%,两者相比差异显著(P<0.05)。血清样本检测中结果与组织样本基本吻合,在性别和吸烟史方面患者基因突变有显著性差异(P<0.05),在癌症分期及类型方面无显著性差异(P>0.05)。结论:非小细胞肺癌患者血清循环DNA检测EGFR基因突变与肿瘤组织检测具有高度的一致性,这对肺癌患者的诊断、筛查和治疗有着重要的意义,为临床检测提供方便、有效的诊断方法。
Objective：To investigate the serum EGFR gene mutations in circulating DNA of non -small cell lung cancer patients. Methods：All 124 cases of non - small cell lung cancer were tested for DNA EGFR gene mutation. Results：Of 124 cases exon 19 mutations in 11 cases, outside the 21st mutations in exon 8 cases, 19 cases detected in serum, the detection rate was 15.3%. EGFR gene testing tissue samples showed：Exon 19 mutations in 27 cases, out- side exon 21 mutations in 13 cases,40 cases detected in serum total detection rate of 32.3%. Mutation detection in tissue samples,and 79 cases of male EGFR mutations detected in 14 cases,the ratio was 17.7% ;45 cases of women EGFR mutations detected in 26 cases, the ratio was 57.8% （P 〈 0.05）. 76 patients with a history of smoking muta- tions detected in 16 cases, the ratio was 21.1% ,48 patients without a history of smoking were detected in 24 cases, the ratio was 50.0% （P 〈 0.05 ）. Conclusion：Patients with non - small cell lung cancer circulating DNA EGFR mu- tations in tumor tissues with a high degree of consistency, this has an important significance in diagnosis of lung cancer patients.
出处
《现代肿瘤医学》
CAS
2015年第3期332-334,共3页
Journal of Modern Oncology
基金
四川省卫生厅重点规划项目(编号:2012BNO.0372)
